2022-04-20| Special

Bio-Europe Spring: 2022 Europe Ophthalmic Medication Market Skyrockets

by GeneOnline
Share To

Biopharma interest in ophthalmic medications is rising, especially in Europe. An overview of Bio-Europe Spring 2022 indicates that about a third of tech/products and a fourth of companies within the conference converge on ophthalmic medication. As 2022 rolls on, it is expected that there will be an uptick in the number of European ophthalmology drugs.

 Related Article: Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations

Rising Eye Health Demands


The prevalence of eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration is expected to increase every year. Over 300 million people were suffering from moderate-severe vision loss worldwide in 2021. In Europe, the incidence rate is more severe and hit an all-time high last year, with over 50 million people affected. Additionally, the ongoing COVID-19 pandemic has resulted in growing negative impacts on ocular health. Research suggests that Europe has been affected more severely than other regions. More than one-third of patients with COVID-19 had ocular involvement and nine out of ten COVID cases have received a subsequent conjunctivitis diagnosis. Moreover, vision problems and deterioration of eye health are on the rise as the digital era continues to evolve.


GO Prime with only $1.49 now

Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
Moderna Welcomes Phase 3 Win For RSV Vaccine
Moving Beyond COVID With mRNA Technology
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!